PL399961A1 - Sposób badania skutecznosci terapeutycznej bakteriofagów - Google Patents

Sposób badania skutecznosci terapeutycznej bakteriofagów

Info

Publication number
PL399961A1
PL399961A1 PL399961A PL39996112A PL399961A1 PL 399961 A1 PL399961 A1 PL 399961A1 PL 399961 A PL399961 A PL 399961A PL 39996112 A PL39996112 A PL 39996112A PL 399961 A1 PL399961 A1 PL 399961A1
Authority
PL
Poland
Prior art keywords
nematodes
infected
bacterial strain
infectious
bacteriophages
Prior art date
Application number
PL399961A
Other languages
English (en)
Other versions
PL219654B1 (pl
Inventor
Malgorzata Lobocka
Aleksandra Głowacka
Kamil Dąbrowski
Monika Sabina Hejnowicz
Agnieszka Gozdek
Beata Weber-Dąbrowska
Andrzej Górski
Joanna Empel
Waleria Hryniewicz
Magdalena Kwiatek
Sylwia Parasion
Romuald Gryko
Original Assignee
Instytut Biochemii I Biofizyki Polskiej Akademii Nauk
Instytut Immunologii i Terapii Doświadczalnej PAN
Narodowy Instytut Leków
Szkoła Główna Gospodarstwa Wiejskiego w Warszawie
Wojskowy Instytut Higieny I Epidemiologii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instytut Biochemii I Biofizyki Polskiej Akademii Nauk, Instytut Immunologii i Terapii Doświadczalnej PAN, Narodowy Instytut Leków, Szkoła Główna Gospodarstwa Wiejskiego w Warszawie, Wojskowy Instytut Higieny I Epidemiologii filed Critical Instytut Biochemii I Biofizyki Polskiej Akademii Nauk
Priority to PL399961A priority Critical patent/PL219654B1/pl
Priority to PCT/EP2013/064870 priority patent/WO2014012872A1/en
Priority to US14/414,486 priority patent/US9678063B2/en
Priority to CA2878824A priority patent/CA2878824C/en
Priority to EP13741984.2A priority patent/EP2872156B1/en
Publication of PL399961A1 publication Critical patent/PL399961A1/pl
Publication of PL219654B1 publication Critical patent/PL219654B1/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5085—Supracellular entities, e.g. tissue, organisms of invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/43504—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates
    • G01N2333/43526—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from worms
    • G01N2333/4353—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from worms from nematodes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Sposób badania skutecznosci terapeutycznej bakteriofagów w leczeniu zakazen szczepem bakteryjnym, charakteryzuje sie tym, ze obejmuje etapy, w których: a) nicienie, zwlaszcza Caenorhabditis elegans, infekuje sie zakaznym szczepem bakteryjnym, b) zainfekowane nicienie kontaktuje sie z badanymi bakteriofagami, a nastepnie c) prowadzi sie dalsza hodowle tych nicieni na sterylnej pozywce, przy czym wzrost zakaznego szczepu bakteryjnego na pozywce lub obnizona przezywalnosc tych nicieni w porównaniu z grupa nicieni hodowanych w tych samych warunkach, ale niezainfekowanych zakaznymi bakteriami i pozbawionych kontaktu z fagiem swiadczy o niskiej skutecznosci terapeutycznej badanego bakteriofaga, a brak wzrostu zakaznego szczepu bakteryjnego oraz podwyzszona przezywalnosc tych nicieni w porównaniu z nicieniami hodowanymi w tych samych warunkach i zainfekowanych zakaznymi bakteriami, ale pozbawionych kontaktu z bakteriofagiem swiadczy o wysokiej skutecznosci terapeutycznej badanego bakteriofaga.
PL399961A 2012-07-14 2012-07-14 Sposób badania skuteczności terapeutycznej bakteriofagów PL219654B1 (pl)

Priority Applications (5)

Application Number Priority Date Filing Date Title
PL399961A PL219654B1 (pl) 2012-07-14 2012-07-14 Sposób badania skuteczności terapeutycznej bakteriofagów
PCT/EP2013/064870 WO2014012872A1 (en) 2012-07-14 2013-07-13 A method of evaluating the therapeutic efficacy of bacteriophages
US14/414,486 US9678063B2 (en) 2012-07-14 2013-07-13 Method of evaluating the therapeutic efficacy of bacteriophages
CA2878824A CA2878824C (en) 2012-07-14 2013-07-13 A method of evaluating the therapeutic efficacy of bacteriophages
EP13741984.2A EP2872156B1 (en) 2012-07-14 2013-07-13 A method of evaluating the therapeutic efficacy of bacteriophages

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL399961A PL219654B1 (pl) 2012-07-14 2012-07-14 Sposób badania skuteczności terapeutycznej bakteriofagów

Publications (2)

Publication Number Publication Date
PL399961A1 true PL399961A1 (pl) 2014-01-20
PL219654B1 PL219654B1 (pl) 2015-06-30

Family

ID=48875650

Family Applications (1)

Application Number Title Priority Date Filing Date
PL399961A PL219654B1 (pl) 2012-07-14 2012-07-14 Sposób badania skuteczności terapeutycznej bakteriofagów

Country Status (5)

Country Link
US (1) US9678063B2 (pl)
EP (1) EP2872156B1 (pl)
CA (1) CA2878824C (pl)
PL (1) PL219654B1 (pl)
WO (1) WO2014012872A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104004748A (zh) * 2014-06-11 2014-08-27 天津出入境检验检疫局动植物与食品检测中心 一种用于植物寄生线虫基因组dna微量提取的裂解液及其应用

Also Published As

Publication number Publication date
US9678063B2 (en) 2017-06-13
US20150192569A1 (en) 2015-07-09
EP2872156A1 (en) 2015-05-20
CA2878824C (en) 2020-12-29
PL219654B1 (pl) 2015-06-30
EP2872156B1 (en) 2017-08-09
CA2878824A1 (en) 2014-01-23
WO2014012872A1 (en) 2014-01-23

Similar Documents

Publication Publication Date Title
NZ735555A (en) Bacteria identification and antimicrobial susceptibility test
EA201591017A1 (ru) Композиции и способы для лечения рака с применением бактерий
MX365159B (es) Cepa aislada de clonostachys rosea para usarse como un agente de control biologico.
AR093061A1 (es) Metodos y composiciones para el tratamiento y control de enfermedades en las plantas
CL2015003120A1 (es) Cepas bacterianas que poseen actividad antimicrobiana y composiciones de control biológico que las contienen
EA201692303A1 (ru) Новая противоинфекционная стратегия против коинфекций, вызванных вирусом гриппа и s.aureus
UY35366A (es) ?genes de toxina y métodos para su uso?.
ECSP20084373A (es) Tiofencarboxamidas sustituidas y análogos de las mismas
MX2016011682A (es) Derivados de polimixina y su uso en terapia de combinacion junto con diferentes antibioticos.
MX356959B (es) Cepa paenibacillus alvei ts-15 y su uso en el control de organismos patogenicos.
ZA202002093B (en) Antibacterial compounds
WO2017218922A8 (en) Compositions and methods for the treatment of bacterial infections
PL386175A1 (pl) Nowe szczepy bakteriofagów do leczenia zakażeń bakteryjnych, zwłaszcza szczepami bakterii lekoopornych rodzaju Enterococcus
PL399961A1 (pl) Sposób badania skutecznosci terapeutycznej bakteriofagów
MX2018014532A (es) Un metodo para reducir la contaminacion de los huevos.
EA201992448A1 (ru) Лечение бактериальной вагинальной инфекции
RU2012110364A (ru) Способ моделирования хронической гнойной костной раны
RU2013130786A (ru) Способ биоремедиации нефтезагрязненных мерзлотных почв
Oh et al. The sub-MIC effect of lysin CF-301 on Staphylococcus aureus (S. aureus)
RU2014153094A (ru) Штамм бактериофага Bacillus anthracis Ф112PRE, используемый для специфической индикации возбудителя сибирской язвы
RU2010151018A (ru) Способ автолиза дрожжей
UY33915A (es) Uso de nifuratel para tratar infecciones causadas por especies de clostridium
RU2012136668A (ru) СПОСОБ ДЕЗИНВАЗИИ ЯИЦ СТРОНГИЛЯТ ЛОШАДЕЙ С ПРИМЕНЕНИЕМ ШТАММОВ БАКТЕРИЙ Bacillus subtilis THП-3, Bacillus subtilis THП-5
MX2014006725A (es) Metodo de transporte y desinfeccion de organos dentarios para aislamiento y cultivo de celulas madre.
MX2022005052A (es) Microorganismos resistentes a los fagos.